Agreement revolves around Factor VIII purification.

BAC and GE Healthcare will together develop and market affinity chromatography media for the purification of therapeutic recombinant Factor VIII.


BAC will provide its CaptureSelect® affinity ligands for  process-scale purification of FVIII for the prevention and treatment of bleeding in patients with haemophilia A.

NewsGenetic diseasesMedicine, Diagnosis, and TherapeuticsSystemic conditionsTherapeuticsX-linked genetic diseasesGE Healthcare
Previous articleStreamlining Biomarker Validation Activities
Next articlePfizer Obtains Licence from Genencor to Aid in Protein-Based Drug Development
Also of Interest
Visual Proteomics: Observing Protein Location in Living Cells
Gene Network Interactions Shed Insight into Breast Cancer Onset and Development
New Insights Could Boost Immunotherapy for Rare Eye Cancer
Skin in the Game: Oruka Takes on Blockbuster Drugs for Psoriasis, Dermatological Disorders
StockWatch: Regeneron Shares Dip as DOJ Alleges Fraudulent Price Reporting
Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline
Related Media
What’s in Store for 2024? Three CEOs Look Ahead and Look Back on “Close to the Edge”
Carl Icahn States His Case for Change at Illumina on "Close to the Edge"
Emerging Markets Collaborate to Succeed in Post-Pandemic World
Breathing Oxygen Back into the Biological Conversation
Global Single-Use Network Support Assurance of Supply
Resins Address Downstream Purification Concerns